190 related articles for article (PubMed ID: 27381050)
1. Pharmacogenomics and the treatment of acute myeloid leukemia.
Megías-Vericat JE; Montesinos P; Herrero MJ; Bosó V; Martínez-Cuadrón D; Poveda JL; Sanz MÁ; Aliño SF
Pharmacogenomics; 2016 Jul; 17(11):1245-1272. PubMed ID: 27381050
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia.
Megias-Vericat JE; Martinez-Cuadron D; Herrero MJ; Alino SF; Poveda JL; Sanz MA; Montesinos P
Curr Drug Metab; 2018; 19(1):55-74. PubMed ID: 29090664
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients.
Cao HX; Miao CF; Yan L; Tang P; Zhang LR; Sun L
J Transl Med; 2017 Nov; 15(1):235. PubMed ID: 29141648
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomics of acute leukemia.
Ansari M; Krajinovic M
Pharmacogenomics; 2007 Jul; 8(7):817-34. PubMed ID: 18240908
[TBL] [Abstract][Full Text] [Related]
5. Current treatment of acute myeloid leukemia.
Roboz GJ
Curr Opin Oncol; 2012 Nov; 24(6):711-9. PubMed ID: 23014187
[TBL] [Abstract][Full Text] [Related]
6. Current and emerging therapies for acute myeloid leukemia.
Robak T; Wierzbowska A
Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia.
Rubnitz JE; Gibson B; Smith FO
Pediatr Clin North Am; 2008 Feb; 55(1):21-51, ix. PubMed ID: 18242314
[TBL] [Abstract][Full Text] [Related]
8. The clinically relevant pharmacogenomic changes in acute myelogenous leukemia.
Emadi A; Karp JE
Pharmacogenomics; 2012 Aug; 13(11):1257-69. PubMed ID: 22920396
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the impact of single-nucleotide polymorphisms on treatment response, survival and toxicity with cytarabine and anthracyclines in patients with acute myeloid leukaemia: a systematic review protocol.
Puty TC; Sarraf JS; Do Carmo Almeida TC; Filho VCB; de Carvalho LEW; Fonseca FLA; Adami F
Syst Rev; 2019 May; 8(1):109. PubMed ID: 31053175
[TBL] [Abstract][Full Text] [Related]
10. A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia.
Megías-Vericat JE; Herrero MJ; Rojas L; Montesinos P; Bosó V; Moscardó F; Martínez-Cuadrón D; Poveda JL; Sanz MÁ; Aliño SF
Pharmacogenomics J; 2016 Feb; 16(1):30-40. PubMed ID: 26644203
[TBL] [Abstract][Full Text] [Related]
11. Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia.
Nakayama H; Tomizawa D; Tanaka S; Iwamoto S; Shimada A; Saito AM; Yamashita Y; Moritake H; Terui K; Taga T; Matsuo H; Kosaka Y; Koh K; Hosoi H; Kurosawa H; Isoyama K; Horibe K; Mizutani S; Adachi S
Pediatr Int; 2017 Oct; 59(10):1046-1052. PubMed ID: 28771903
[TBL] [Abstract][Full Text] [Related]
12. Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review.
Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Montesinos P
Ann Hematol; 2018 Jul; 97(7):1115-1153. PubMed ID: 29680875
[TBL] [Abstract][Full Text] [Related]
13. Induction therapy in acute myeloid leukemia: intensifying and targeting the approach.
Fernandez HF; Rowe JM
Curr Opin Hematol; 2010 Mar; 17(2):79-84. PubMed ID: 20087177
[TBL] [Abstract][Full Text] [Related]
14. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
Creutzig U; Ritter J; Zimmermann M; Reinhardt D; Hermann J; Berthold F; Henze G; Jürgens H; Kabisch H; Havers W; Reiter A; Kluba U; Niggli F; Gadner H
J Clin Oncol; 2001 May; 19(10):2705-13. PubMed ID: 11352963
[TBL] [Abstract][Full Text] [Related]
15. New treatment for acute myelogenous leukemia.
DiNardo CD; Cortes JE
Expert Opin Pharmacother; 2015 Jan; 16(1):95-106. PubMed ID: 25480777
[TBL] [Abstract][Full Text] [Related]
16. Evolving Therapies in Acute Myeloid Leukemia: Progress at Last?
DeAngelo DJ; Stein EM; Ravandi F
Am Soc Clin Oncol Educ Book; 2016; 35():e302-12. PubMed ID: 27249736
[TBL] [Abstract][Full Text] [Related]
17. Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies.
Megías-Vericat JE; Rojas L; Herrero MJ; Bosó V; Montesinos P; Moscardó F; Poveda JL; Sanz MÁ; Aliño SF
Pharmacogenomics J; 2015 Apr; 15(2):109-18. PubMed ID: 25558979
[TBL] [Abstract][Full Text] [Related]
18. Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group.
Klein K; Kaspers G; Harrison CJ; Beverloo HB; Reedijk A; Bongers M; Cloos J; Pession A; Reinhardt D; Zimmerman M; Creutzig U; Dworzak M; Alonzo T; Johnston D; Hirsch B; Zapotocky M; De Moerloose B; Fynn A; Lee V; Taga T; Tawa A; Auvrignon A; Zeller B; Forestier E; Salgado C; Balwierz W; Popa A; Rubnitz J; Raimondi S; Gibson B
J Clin Oncol; 2015 Dec; 33(36):4247-58. PubMed ID: 26573082
[TBL] [Abstract][Full Text] [Related]
19. HAG regimen improves survival in adult patients with hypocellular acute myeloid leukemia.
Hu X; Fu W; Wang L; Gao L; Lü S; Xi H; Qiu H; Chen L; Chen J; Ni X; Xu X; Zhang W; Yang J; Wang J; Song X
Oncotarget; 2016 Jan; 7(3):3623-34. PubMed ID: 26497216
[TBL] [Abstract][Full Text] [Related]
20. [High-intensity chemotherapy versus palliative chemotherapy in patients over 60 years with acute myeloid leukemia].
Medrano-Contreras J; Talavera-Piña JO; Guerrero-Rivera S; Gutiérrez-Espíndola GR; Gómez-Cortés C; Pérez-Rocha JF; Terreros-Muñoz E; Meillón-García LA
Rev Med Inst Mex Seguro Soc; 2016; 54 Suppl 2():S148-55. PubMed ID: 27561018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
